查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
數位生物標誌物市場規模、份額和趨勢分析報告：按類型（可穿戴設備、移動應用、傳感器）、臨床實踐、治療領域、用途、地區、細分市場、2022-2030預測
市場調查報告書
商品編碼
1147557

數位生物標誌物市場規模、份額和趨勢分析報告：按類型（可穿戴設備、移動應用、傳感器）、臨床實踐、治療領域、用途、地區、細分市場、2022-2030預測

Digital Biomarkers Market Size, Share & Trends Analysis Report By Type (Wearable, Mobile based Applications, Sensors), By Clinical Practice, By Therapeutic Area, By End-use, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

數位生物標誌物市場增長和趨勢

根據 Grand View Research, Inc. 的最新報告，到 2030 年，全球數字生物標誌物市場規模預計將達到 139.6616 億美元，預測期內的複合年增長率為 21.9%。由於最近的進步和對遠程技術的日益接受，數位生物標記物的市場預計將在整個預測期內擴大。可穿戴和移動技術的進步推動了構成數字生物標記市場最大部分的遠程數據收集技術的發展。此外，互聯網的日益普及進一步推動了這一細分市場。

特別是語音數位生物標誌物最近出現並具有巨大的商業潛力。可以通過錄音、手機和可穿戴設備等患者自有技術輕鬆收集數據。語音生物標誌物有可能通過加強對身體或精神疾病的早期干預和預先識別，從而在預測期內促進市場擴張，從而減輕醫療保健系統的負擔並改善患者的治療效果。

此外，玩家也開始探索語音數位生物標誌物，以在預測期內獲得市場佔有率並進一步增加收入市場份額。例如，2021 年 10 月，Sonde Health 宣布推出支持語音的心理健康監測技術平台。

此外，由於慢性病和神經退行性疾□□病的患病率上升以及對加強藥物開發以成功控制這些疾病的需求不斷增加，市場在預測期內將顯著增長。與傳統的臨床試驗過程不同，數字生物標誌物可以加速新藥開發。

根據分散式臨床試驗平台提供商之一 Medable 的一項研究，85.0% 的所有臨床試驗都經歷了某種延遲，每天的經濟影響在 60 萬美元到 800 萬美元之間。據說分散式臨床試驗最多可將 2 期試驗時間縮短 1-3 個月。因此，製藥商正在投資 DCT 數字生物標誌物，這有望推動市場擴張。例如，2022 年 3 月，阿斯利康宣布向總部位於英國的 HUMA 投資 3300 萬美元，該公司提供基於遠程數字生物標誌物的分散式臨床試驗。這種夥伴關係將加速 DCT 的採用。

以遠見為導向的市場進入者擴大他們的決策，以加強他們在全球數字生物標誌物市場的地位，利用他們未來成功所需的技術能力和服務的廣度。我們正在超越典型的供應商。這些公司採取了多種戰略，包括產品發布、合資企業和併購。例如，2022 年 4 月，輝瑞公司宣布收購 ResApp，這是一家總部位於澳大利亞的初創公司，該公司使用人工智能創建了一款應用程序，該應用程序使用患者的咳嗽聲音來衡量和確定呼吸系統問題的嚴重程度。

數位生物標誌物市場報告要點

心血管和代謝疾病 (CVMD) 將在 2021 年佔治療領域部分的最高收入份額，超過 20.0%，隨著全球患者人群中心血管疾病的患病率上升。因此，預計將繼續成為未來的主要參與者。另一方面，由於 COVID-19 和新興技術，呼吸系統疾病市場收入份額預計在預測期內以最快的速度增長

診斷數字生物標誌物在 2021 年佔臨床實踐部分的最大收入份額，原因是越來越多地使用用於臨床疾病和日常生活的診斷監測。此外，用於監測的數字生物標誌物有望在預測期內實現最快的收入增長

由於尖端的可穿戴智能手錶等新產品的推出，2021 年可穿戴設備在數字生物標記類型細分市場中的收入份額超過 39.0%。由於全球智能手機的廣泛使用，基於移動的應用程序的收入份額預計將在預測期內以最快的速度增長。此外，新技術和傳感器的使用越來越多，預計將在預測期內產生激烈的競爭。

由於適應症的增加以及對具有成本效益的臨床試驗和產品分析策略的需求增加，醫療保健公司在 2021 年的最終用途類別中佔據了超過 50.0% 的最大市場份額。

由於其完善的先進醫療基礎設施和研發活動的大量支出，北美將在 2021 年佔據市場主導地位，佔總收入的份額超過 59.0%。此外，歐洲將在預測期內表現出最快的增長

主要參與者還通過合作夥伴關係、收購、合併和產品發佈為市場的擴張做出貢獻。例如，在 2021 年，Medable 將與數字生物標誌物公司 Aural Analytics 合作，測量遠處的言語模式並監測健康狀況和衰退階段

內容

第 1 章調查方法及範圍

  • 市場細分和範圍
  • 調查方法
  • 資訊採購
    • 購買的數據庫：
    • GVR 內部數據庫
    • 次要資訊
    • 初步調查
    • 初步調查的內容
  • 資訊或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 模型詳細資訊
    • 商品流分析（模型 1）
      • 方法 1：商品流方法
  • 二級資訊列表
  • 主要資訊列表
  • 報告的目的

第 2 章執行摘要

  • 市場展望
  • 2021 年數位生物標誌物市場概覽

第 3 章數位生物標誌物市場變量、趨勢和範圍

  • 市場系列展望
    • 母公司市場展望
    • 輔助市場展望
  • 描繪滲透率和增長前景
  • 數位生物標誌物市場動態
    • 市場促進因素分析
      • 遠程技術的最新創新和日益普及
      • 智能手機使用率的增加和新型可穿戴設備的出現
      • 擴大治療範圍
      • 增加對分散式臨床試驗的投資
    • 市場抑制因素分析
      • 數據隱私問題
      • 缺乏對新興經濟學的認識和熟練的專業人員
  • 數位生物標誌物市場分析工具：波特五力分析
    • 供應商的力量
    • 買家的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的敵對關係
  • PESTEL 分析
    • 政治和法律格局
    • 社交情況
    • 技術概況
    • 環境分析
  • 監管框架
  • 技術概覽
  • 價格分析
  • COVID-19 影響分析
    • 當前和未來的影響分析
    • COVID-19 對市場參與者的影響

第 4 章競爭格局

  • 市場參與分類
  • 上市公司
    • 公司市場分析
    • 協同分析：主要交易和戰略聯盟
  • 市場參與者的詳細列表

第 5 章數位生物標誌物市場：細分分析，按類型，2017-2030（百萬美元）

  • 類型變化分析，2021 年和 2030 年
    • 可穿戴設備
    • 基於移動的應用程序
    • 傳感器
    • 其他

第 6 章數位生物標誌物市場：細分分析，按臨床實踐，2017-2030（百萬美元）

  • 2021 年和 2030 年臨床實踐變化分析
    • 診斷數位生物標誌物
    • 監測數位生物標誌物
    • 預測和預後數位生物標誌物
    • 其他

第 7 章。數位生物標誌物市場：細分分析，按治療領域，2017-2030 年（百萬美元）

  • 治療變異分析，2021 年和 2030 年
    • 心血管和代謝紊亂 (CVMD)
    • 呼吸系統疾病
    • 精神障礙
    • 睡眠和運動疾病
    • 神經系統疾病
    • 肌肉骨骼疾病
    • 其他

第 8 章數位生物標誌物市場：細分分析，按最終用途，2017-2030（百萬美元）

  • 2021 年和 2030 年最終用途變化分析
    • 醫療保健公司
    • 醫療保健提供者
    • 付款人
    • 其他

第 9 章數位生物標誌物市場：按類型、臨床實踐、治療領域和最終用途（百萬美元）分列的區域市場分析，2017-2030

  • 2017-2030 年市場規模、預測、數量和趨勢分析
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 荷蘭
    • 意大利
    • 瑞士
  • 亞太地區
    • 日本
    • 中國
    • 澳大利亞
    • 印度
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
  • 多邊環境協定
    • 南非
    • 以色列

第 10 章公司簡介

  • ActiGraph LLC
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • AliveCor Inc
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Koneksa
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Amgen Inc.
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Biogen Inc.
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Altoida Inc
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • IXICO plc
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Adherium Limited
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Empatica Inc
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Huma
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • VivoSense
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • ResApp（Pfizer）
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
Product Code: GVR-4-68039-989-3

Digital Biomarkers Market Growth & Trends:

The global digital biomarkers market size is expected to reach USD 13,966.16 million by 2030, registering a CAGR of 21.9% during the forecast period, according to a new report by Grand View Research, Inc. Due to the rising acceptance of recent advancements and remote technologies, the market for digital biomarkers is anticipated to expand throughout the forecast period. Development of the remote data collecting technologies, which make up the largest segment of the market for digital biomarkers, has been propelled by the improvements in wearable and mobile technology. Additionally, this market segment is being further assisted by the growing use of the internet.

Vocal digital biomarkers in particular have lately come into existence and offer enormous business development potential. They enable easy data collection through voice recordings and through patient-owned technology like cell phones, wearables, and other devices. Vocal biomarkers are being utilized more frequently, which might ease the strain on the healthcare systems and improve patient outcomes by enhancing early intervention and before-time identification of physical or mental illnesses, boosting the market's expansion during the forecast period.

Furthermore, in order to acquire market presence and further boost its revenue market share during the forecast, players have also begun exploring the vocal digital biomarkers. For instance, in October 2021, Sonde health launched a voice-enabled mental fitness monitoring technology platform.

Additionally, the market is anticipated to experience substantial expansion during the forecast period due to the rising prevalence of chronic diseases and neurodegenerative diseases, as well as the growing need for enhanced drug development to successfully control these diseases. In comparison to the conventional clinical trial process, digital biomarkers accelerate the development of new drugs.

According to a study by one of the well-known decentralized trial platform providers, Med able, 85.0% of all clinical trials experience some sort of delay, with the financial impact of delays costing between USD 600,000 and USD 8 million per day, decentralized clinical trials could save up to 1 to 3 months of time in phase 2 studies. As a result, medicine manufacturers are spending money on a digital biomarker for DCT, which is anticipated to fuel market expansion. For instance, AstraZeneca stated in March 2022 that it had invested USD 33.0 million in Huma, a UK-based company that provides decentralized clinical trials based on remote digital biomarkers. Through this alliance, the company will quicken the adoption of DCT.

Forward-thinking market participants are expanding their decisions and moving beyond typical suppliers in order to strengthen the company's position in the global market for digital biomarkers by utilizing the wide range of technology capabilities and services required for future success. These companies have employed a variety of strategies such as product launches, joint ventures, and mergers & acquisitions. For instance, in April 2022, Pfizer acquired ResApp, an Australian- based startup that had created an app that uses artificial intelligence to gauge and determine the severity of respiratory problems using the coughing voice of a patient.

Digital Biomarkers Market Report Highlights:

  • Cardiovascular and metabolic disorders (CVMD) had the highest revenue share of more than 20.0% in the therapeutic area segment in 2021 and is anticipated that it will continue to have a significant major presence given the rising prevalence of cardiovascular diseases among patient populations around the globe. On the other hand, due to COVID-19 and emerging new technologies, it is anticipated that during the forecast period, market revenue share for respiratory disorders will expand at the fastest rate
  • Due to the growing use of diagnostic monitoring meant for clinical disease and daily living, diagnostic digital biomarkers had the largest revenue share in the clinical practice segment in 2021. Moreover, the fastest revenue growth is anticipated for monitoring digital biomarkers during the forecast period
  • Wearable had a revenue share of more than 39.0% in the digital biomarker type segment in 2021, due to the release of new, cutting-edge wearable smart watches and other products. As a result of the extensive usage of smartphones, worldwide, it is anticipated that revenue share growth for mobile-based applications would happen at the fastest rate during the forecast period. Additionally, rising usage of new technologies, and sensors, would also confront intense competition during the forecast period
  • Healthcare companies hold the largest, more than 50.0% market share within the end-use category, in 2021, as a result of the rising indications and demands for cost-effective clinical trial and product analysis strategies
  • North America dominated the market in 2021 and generated more than 59.0% share of the total revenue, as a result of its well-established advanced healthcare infrastructure and large expenditure in R&D activities. Furthermore, Europe would see the fastest rate of growth during the forecast period
  • By engaging in partnerships, acquisitions, mergers, and product launches, key companies also help the market to expand. For instance, in 2021, Med able collaborated with the digital biomarkers business Aural Analytics to measure distant speech patterns and monitor their well-being and stage of decline

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
      • 1.6.1.1 Approach 1: Commodity Flow Approach
  • 1.7 List of Secondary Sources
  • 1.8 List of Primary Sources
  • 1.9 Report Objectives

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Digital BiomarkersMarket Summary, 2021

Chapter 3 Digital Biomarkers Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Digital Biomarkers Market Dynamics
    • 3.3.1 Market Driver Analysis
      • 3.3.1.1 Increased Popularity of Recent Innovations and Remote Technologies
      • 3.3.1.2 Rising Usage of Smartphones and The Emergence of New Wearables
      • 3.3.1.3 Expanding Therapeutic Area Application
      • 3.3.1.4 Increasing Investment in Decentralized Clinical Trials
    • 3.3.2 Market Restraints Analysis
      • 3.3.2.1 Concerns about Data Privacy
      • 3.3.2.1 Lack of Awareness and Poor Skilled Professionals in Emerging Economics
  • 3.4 Digital Biomarkers Market Analysis Tools: Porter's Five Forces Analysis
    • 3.4.1 Supplier Power
    • 3.4.2 Buyer Power
    • 3.4.3 Threat Of Substitutes
    • 3.4.4 Threat Of New Entrants
    • 3.4.5 Competitive Rivalry
  • 3.5 Pestel Analysis
    • 3.5.1 Political & Legal Landscape
    • 3.5.2 Social Landscape
    • 3.5.3 Technology Landscape
    • 3.5.4 Environmental Analysis
  • 3.6 Regulatory Framework
  • 3.7 Technology Overview
  • 3.8 Pricing Analysis
  • 3.9 Covid-19 Impact Analysis
    • 3.9.1 Current And Future Impact Analysis
    • 3.9.2 Impact Of Covid-19 On Market Players

Chapter 4 Competitive Landscape

  • 4.1 Market participation categorization
  • 4.2 Public Companies
    • 4.2.1 Company Market Position Analysis
    • 4.2.2 Synergy Analysis: Major Deals & Strategic Alliances
  • 4.3 Detailed list of market players

Chapter 5 Digital Biomarkers Market: Segment Analysis, by type, 2017 - 2030 (USD Million)

  • 5.1 Type Movement Analysis, 2021 & 2030
    • 5.1.1 Wearable
      • 5.1.1.1 Wearable Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 5.1.2 Mobile Based Applications
      • 5.1.2.1 Mobile Based Applications Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 5.1.3 Sensors
      • 5.1.3.1 Sensors Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 5.1.4 Others
      • 5.1.4.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)

Chapter 6 Digital Biomarkers Market: Segment Analysis, by Clinical Practice, 2017 - 2030 (USD Million)

  • 6.1 Clinical Practice Movement Analysis, 2021 & 2030
    • 6.1.1 Diagnostic Digital Biomarkers
      • 6.1.1.1 Diagnostic Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 6.1.2 Monitoring Digital Biomarkers
      • 6.1.2.1 Monitoring Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 6.1.3 Predictive and Prognostic Digital Biomarkers
      • 6.1.3.1 Predictive and Prognostic Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 6.1.4 Others
      • 6.1.4.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)

Chapter 7 Digital Biomarkers Market: Segment Analysis, by Therapeutic Area, 2017 - 2030 (USD Million)

  • 7.1 Therapeutic Area Movement Analysis, 2021 & 2030
    • 7.1.1 Cardiovascular and Metabolic Disorders (CVMD)
      • 7.1.1.1 Cardiovascular and Metabolic Disorders (CVMD) Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 7.1.2 Respiratory Disorders
      • 7.1.2.1 Respiratory Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 7.1.3 Psychiatric Disorders
      • 7.1.3.1 Psychiatric Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 7.1.4 Sleep & Movement Disease
      • 7.1.4.1 Sleep & Movement Disease Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 7.1.5 Neurological Disorders
      • 7.1.5.1 Neurological Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 7.1.6 Musculoskeletal Disorders
      • 7.1.6.1 Musculoskeletal Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 7.1.7 Others
      • 7.1.7.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)

Chapter 8 Digital Biomarkers Market: Segment Analysis, by End-Use, 2017 - 2030 (USD Million)

  • 8.1 End-Use Movement Analysis, 2021 & 2030
    • 8.1.1 Healthcare Companies
      • 8.1.1.1 Healthcare Companies Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 8.1.2 Healthcare Providers
      • 8.1.2.1 Healthcare ProvidersMarket Estimates and Forecasts, 2017 - 2030 (Million)
    • 8.1.3 Payers
      • 8.1.3.1 Payers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 8.1.4 Others
      • 8.1.4.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)

Chapter 9 Digital Biomarkers Market: Regional Market Analysis, by type, clinical practice, therapeutic area, and end-Use, 2017 - 2030 (USD Million)

  • 9.1 Market Size, & Forecasts, Volume, and Trend Analysis, 2017 to 2030
  • 9.2 North America
    • 9.2.1 North America Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.2.2 U.S.
      • 9.2.2.1 U.S. Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.2.3 Canada
      • 9.2.3.1 Canada Digital Biomarkers Market Estimates and Forecasts, 2017 -2030 (Million)
  • 9.3 Europe
    • 9.3.1 Europe Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.3.2 U.K.
      • 9.3.2.1 U.K. Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.3.3 Germany
      • 9.3.3.1 Germany Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.3.4 Netherlands
      • 9.3.4.1 Netherlands Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.3.5 Italy
      • 9.3.5.1 Italy Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.3.6 Switzerland
      • 9.3.6.1 Switzerland Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.4.2 Japan
      • 9.4.2.1 Japan Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.4.3 China
      • 9.4.3.1 China Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.4.4 Australia
      • 9.4.4.1 Australia Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.4.5 India
      • 9.4.5.1 India Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.4.6 South Korea
      • 9.4.6.1 South Korea Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.5 Latin America
    • 9.5.1 Latin America Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.5.2 Brazil
      • 9.5.2.1 Brazil Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.5.3 Mexico
      • 9.5.3.1 Mexico Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.6 MEA
    • 9.6.1 MEA Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.6.2 South Africa
      • 9.6.2.1 South Africa Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.6.3 Israel
      • 9.6.3.1 Israel Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)

Chapter 10 Company Profiles

  • 10.1 ActiGraph LLC
    • 10.1.1 Company Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Benchmarking
    • 10.1.4 Strategic Initiatives
  • 10.2 AliveCor Inc
    • 10.2.1 Company Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Benchmarking
    • 10.2.4 Strategic Initiatives
  • 10.3 Koneksa
    • 10.3.1 Company Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Benchmarking
    • 10.3.4 Strategic Initiatives
  • 10.4 Amgen Inc.
    • 10.4.1 Company Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Benchmarking
    • 10.4.4 Strategic Initiatives
  • 10.5 Biogen Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Benchmarking
    • 10.5.4 Strategic Initiatives
  • 10.6 Altoida Inc
    • 10.6.1 Company Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Benchmarking
    • 10.6.4 Strategic Initiatives
  • 10.7 IXICO plc
    • 10.7.1 Company Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Benchmarking
    • 10.7.4 Strategic Initiatives
  • 10.8 Adherium Limited
    • 10.8.1 Company Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Benchmarking
    • 10.8.4 Strategic Initiatives
  • 10.9 Empatica Inc
    • 10.9.1 Company Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Benchmarking
    • 10.9.4 Strategic Initiatives
  • 10.10 Huma
    • 10.10.1 Company Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Benchmarking
    • 10.10.4 Strategic Initiatives
  • 10.11 VivoSense
    • 10.11.1 Company Overview
    • 10.11.2 Financial Performance
    • 10.11.3 Product Benchmarking
    • 10.11.4 Strategic Initiatives
  • 10.12 ResApp (Pfizer)
    • 10.12.1 Company Overview
    • 10.12.2 Financial Performance
    • 10.12.3 Product Benchmarking
    • 10.12.4 Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of key companies
  • Table 3. North America Digital Biomarkers market, by country, 2017 - 2030 (USD Million)
  • Table 4. North America Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 5. North America Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 6. North America Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 7. North America Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 8. U.S. Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 9. U.S. Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 10. U.S. Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 11. U.S. Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 12. Canada Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 13. Canada Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 14. Canada Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 15. Canada Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 16. Europe Digital Biomarkers market, by country, 2017 - 2030 (USD Million)
  • Table 17. Europe Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 18. Europe Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 19. Europe Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 20. Europe Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 21. U.K. Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 22. U.K. Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 23. U.K. Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 24. U.K. Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 25. Germany Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 26. Germany Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 27. Germany Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 28. Germany Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 29. Netherlands Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 30. Netherlands Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 31. Netherlands Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 32. Netherlands Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 33. Italy Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 34. Italy Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 35. Italy Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 36. Italy Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 37. Switzerland Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 38. Switzerland Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 39. Switzerland Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 40. Switzerland Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 41. Asia Pacific Digital Biomarkers market, by country, 2017 - 2030 (USD Million)
  • Table 42. Asia Pacific Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 43. Asia Pacific Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 44. Asia Pacific Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 45. Asia Pacific Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 46. China Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 47. China Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 48. China Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 49. China Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 50. Japan Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 51. Japan Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 52. Japan Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 53. Japan Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 54. India Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 55. India Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 56. India Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 57. India Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 58. Australia Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 59. Australia Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 60. Australia Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 61. Australia Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 62. South Korea Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 63. South Korea Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 64. South Korea Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 65. South Korea Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 66. LATAM Digital Biomarkers market, by country, 2017 - 2030 (USD Million)
  • Table 67. LATAM Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 68. LATAM Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 69. LATAM Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 70. LATAM Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 71. Brazil Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 72. Brazil Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 73. Brazil Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 74. Brazil Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 75. Mexico Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 76. Mexico Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 77. Mexico Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 78. Mexico Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 79. MEA Digital Biomarkers market, by country, 2017 - 2030 (USD Million)
  • Table 80. MEA Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 81. MEA Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 82. MEA Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 83. MEA Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 84. South Africa Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 85. South Africa Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 86. South Africa Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 87. South Africa Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 88. Israel Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 89. Israel Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 90. Israel Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 91. Israel Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 92. Global Digital Biomarkers market, by region, 2017 - 2030 (USD Million)
  • Table 93. Global Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 94. Global Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 95. Global Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 96. Global Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD Modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Segment-Based Penetration Model
  • Fig. 11 Market summary (2021, Million)
  • Fig. 12 Penetration & growth prospect mapping
  • Fig. 13 Market variable analysis
  • Fig. 14 Market driver relevance analysis (Current & future impact)
  • Fig. 15 Market restraint relevance analysis (Current & future impact)
  • Fig. 16 Digital Biomarkers Market: By Type Movement Analysis, 2021 & 2030
  • Fig. 17 Wearable Market, 2017 - 2030 (Million)
  • Fig. 18 Mobile based Applications Market, 2017 - 2030 (Million)
  • Fig. 19 Sensors Market, 2017 - 2030 (Million)
  • Fig. 20 Others Market, 2017 - 2030 (Million)
  • Fig. 21 Digital Biomarkers Market: By Clinical Practice Movement Analysis, 2021 & 2030
  • Fig. 22 Diagnostic digital biomarkers market, 2017 - 2030 (Million)
  • Fig. 23 Monitoring digital biomarkers market, 2017 - 2030 (Million)
  • Fig. 24 Predictive and Prognostic digital biomarkers market, 2017 - 2030 (Million)
  • Fig. 25 Others digital biomarker market, 2017 - 2030 (Million)
  • Fig. 26 Digital Biomarkers Market: By Therapeutic Area Movement Analysis, 2021 & 2030
  • Fig. 27 Cardiovascular and metabolic disorders (CVMD) market, 2017 - 2030 (Million)
  • Fig. 28 Respiratory disorders market, 2017 - 2030 (Million)
  • Fig. 29 Psychiatric disorders market, 2017 - 2030 (Million)
  • Fig. 30 Sleep & movement disease market, 2017 - 2030 (Million)
  • Fig. 31 Neurological disorders market, 2017 - 2030 (Million)
  • Fig. 32 Musculoskeletal disorders market, 2017 - 2030 (Million)
  • Fig. 33 Others market, 2017 - 2030 (Million)
  • Fig. 34 Digital Biomarkers Market: By End-Use Movement Analysis, 2021 & 2030
  • Fig. 35 Healthcare companies market, 2017 - 2030 (Million)
  • Fig. 36 Healthcare Providers market, 2017 - 2030 (Million)
  • Fig. 37 Payers market, 2017 - 2030 (Million)
  • Fig. 38 Others market, 2017 - 2030 (Million)
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 Regional outlook, 2021 & 2030
  • Fig. 41 North America Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 42 U.S. Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 43 Canada Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 44 Europe Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 45 U.K. Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 46 Germany Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 47 Netherlands Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 48 Italy Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 49 Switzerland Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 50 Asia Pacific Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 51 Japan Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 52 China Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 53 India Digital Biomarkers Market, 2017- 2030 (Million)
  • Fig. 54 South Korea Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 55 Australia Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 56 Latin America Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 57 Brazil Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 58 Mexico Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 59 MEA Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 60 South Africa Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 61 Israel Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 62 Market Participation Categorization
  • Fig. 63 Company market position analysis